We're glad you asked! At SkinVision, we're driven by transparency, honesty, and the deeply rooted mission to save lives by enabling early detection of skin cancer.
Here's a breakdown of how your payment contributes to our mission and what it enables us to do:
- Expert Dermatological Insight: Your fees enable us to offer the expertise of our dedicated dermatologists. With a sensitivity rate of approximately 90%, our advanced algorithm is a critical tool in early skin cancer detection.
- Fighting Skin Cancer Together: Every check you perform with SkinVision is a step towards early skin cancer detection. Your choice to use SkinVision supports our mission to combat skin cancer, aiding us in saving lives every day.
- Commitment to Quality and Security: We’re proud to be a regulated CE marked medical device, a testament to our commitment to maintaining the highest quality management systems (ISO 13485), to ensure we provide you a service of high efficacy and safety. In keeping your personal and health data safe and secure, we also continue to maintain our information security management systems (ISO 27001). To read more about SkinVision's ISO certifications, visit SkinVision's website.
- Research and Continuous Improvement: SkinVision believes and is obligated as a medical device to implement an evidence-based approach to continuously measure the performance of the device and collect further evidence on its safety and effectiveness.
Thus, we invest time, energy and money to ensure that our service is clinically validated so that we can bring you a product that is backed by clinical evidence.
The SkinVision Service has been the object of multiple third party studies, performed by prestigious academic institutions, including Erasmus Medical Center of Rotterdam (EMC) and data published in influential journals.
In 2022, Erasmus Medical Center (EMC) published a prospective Multicenter Diagnostic Accuracy Study further validating the performance of the SkinVision Service [1].
This study showed us that:
SkinVision can detect approximately 90% of skin cancer cases. To compare: the sensitivity of general practitioners ranges between 61% and 66%[2-4].
References:
[1] Sangers et al., 2022 - DOI: 10.1159/000520474
[2] Ahmadi et al., 2018 - DOI: 10.1111/jdv.14484
[3] Beecher et al., 2018 - DOI: 10.1007/s11845-018-1788-z
[4] Corbo et al., 2012 - DOI: 10.1177/120347541201600410